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Bottromycins represent a promising class of anti-
biotics binding to the therapeutically unexploited
A-site of the bacterial ribosome. By inhibiting
translation they are active against clinically impor-
tant pathogens, such as vancomycin-resistant
Enterococci. Structurally, bottromycins are heavily
modified peptides exhibiting various unusual bio-
synthetic features. To set the stage for compound
modification and yield optimization, we identified
the biosynthetic gene cluster, used synthetic bio-
technology approaches to establish and improve
heterologous production, and generated analogs
by pathway genetic engineering. We unambiguously
identified three radical SAM methyltransferase-
encoding genes required for various methylations
at unactivated carbons yielding tert-butyl valine,
methyl-proline, and b-methyl-phenylalanine resi-
dues, plus a gene involved in aspartate methyl-ester
formation. Evidence for the formation of the exo-
thiazole unit and for a macrocyclodehydration
mechanism leading to amidine ring formation is
provided.
INTRODUCTION
One of the most prominent global public health threats is caused
by antibiotic resistance in conjunction with new and reoccurring
infectious diseases. In addition, antimicrobial research in phar-
maceutical companies is challenged by a severe disproportion
between the degree of investment and the expected profit in
the course of drug development. Therefore, access to new hit-
and-lead structures addressing novel targets and/or represent-
ing new chemical scaffolds exhibiting activity against multi-
drug-resistant bacteria is of utmost importance (Fischbach and
Walsh, 2009; Newman and Cragg, 2012; Li and Vederas, 2009).
Bottromycins were discovered as antibacterial peptides
with promising activity against Gram-positive bacteria and
mycoplasma from the fermentation broth of Streptomyces
bottropensis (Waisvisz et al., 1957a, 1957b, 1957c; Waisvisz1278 Chemistry & Biology 19, 1278–1287, October 26, 2012 ª2012 Eand van der Hoeven, 1958; Tanaka et al., 1968). Later on it
was shown that their antibacterial ability extends to methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resis-
tant Enterococci (VRE) (Shimamura et al., 2009). The structure
elucidation process involved several chemical revisions (Naka-
mura et al., 1965a, 1965b, 1965c, 1966, 1967; Takahashi et al.,
1976; Schipper, 1983) and ultimately led to the assignment of 1
(Figure 1), which was recently confirmed by total synthesis (Shi-
mamura et al., 2009). Mode of action studies revealed the amino-
acyl-tRNA binding site (A site) on the 50S ribosome as the target
of bottromycins, ultimately leading to the inhibition of protein
synthesis (Otaka and Kaji, 1976, 1981, 1983). As this site is
currently not addressed by clinically used antibiotics, no cross-
resistance was observed, and bottromycins are regarded as
promising leads to be developed as novel anti-infectives, with re-
newed interest even in medicinal chemistry (Gouda et al., 2012).
Bottromycins represent octapeptides exhibiting an internal
tetrapeptide cycle formed via a unique amidine linkage. The
compound harbors an exo-thiazole and several unnatural amino
acids, which carry methyl-groups at nonactivated carbons,
posing additional challenges for total synthetic approaches
aimed toward drug development.
As a valid alternative to total synthesis, biosynthetic engi-
neering can be envisaged to improve structure and yield of any
microbial natural product eventually resulting in fermentative
production (Fischbach and Voigt, 2010). To achieve this goal
the underlying principles of compound production need to be
understood, and thus identification of the biosynthetic genes is
mandatory. In principle, there are two natural ways for the
production of highly modified and bioactive peptide scaffolds:
biosynthesis can be achieved in a thiotemplated fashion on large
multienzymatic systems termed nonribosomal peptide synthe-
tases (NRPS), which were intensively studied in the past
decades (Finking and Marahiel, 2004; Schwarzer et al., 2003).
Alternatively, and only recently described as more common
than originally anticipated, complex peptides can also be bio-
synthesized starting from simple, ribosomally made precursor
peptides undergoing intriguing modification steps (McIntosh
et al., 2009; Nolan and Walsh, 2009; Oman and van der Donk,
2010). Nonribosomally synthesized peptides (NRPs) and the
latter compounds of ribosomal origin (RPs) differ mainly in the
construction of the core-scaffold as RPs are limited in structural
diversity by incorporation of the canonical proteinogenic amino
acids only. However, they can be extensively posttranslationallylsevier Ltd All rights reserved
Figure 1. Maturation of the Ribosomal Bottromycin Peptide Scaffold
The bottromycin precursor peptide consists of the core peptide as well as a C-terminal extension (underlined) likely serving as recognition sequence. Maturation
of the bottromycin peptide scaffold requires a number of posttranslational modifications (highlighted in gray), the timing of which is currently unknown. These
include various methylations and proteolytic digestion as well as ‘‘macrocyclodehydration’’ and thiazole ring formation (proposed mechanisms for the latter two
are boxed, for explanations see subsection ‘‘In Silico Analysis of the Bottromycin Biosynthetic Pathway’’). R, H or Me; X, OH or MTADFLNDDPNNAELSALE
MEELESWGAWDGEATS.
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state (McIntosh et al., 2009; Oman and van der Donk, 2010).
NRPS, in contrast, incorporate during chain assembly numerous
‘‘unnatural’’ amino acids and are thought to undergo less exten-
sive post-NRPS modifications. However and despite their vastly
different core biosynthetic routes, RPs and NRPs share many
postassemblymodifications, which are often required for biolog-
ical activity. These include heterocyclizations, methylations, and
glycosylations, just to name a few (Walsh et al., 2001; McIntosh
et al., 2009; Oman and van der Donk, 2010). In NRPS the
required enzymatic functionalities are optionally incorporated
into the megasynthetases. As discussed above it is difficult to
predict from the chemical structure whether modified peptides
are based on NRP and RP assembly logic. Therefore, retrobio-
synthetic analysis of bottromycin did not yield an assignment
of the type of biosynthetic pathway to be expected.Chemistry & Biology 19, 1278–1Motivated by the promising activity and the chemical
uniqueness of the bottromycin scaffold, we set out to identify
the biosynthetic gene locus in the terrestrial actinomycete
Streptomyces sp. BC16019, which was shown to produce
bottromycin A2, B2, and C2 (Lerchen et al., 2006). This work
identified a ribosomal locus required for bottromycin biosyn-
thesis and set the stage for synthetic biotechnology approaches
toward structure and yield improvement. We heterologously
expressed the biosynthetic pathway and optimized initially low
bottromycin production titers. Using pathway engineering we
were able to assign each of the five unusual methylation
reactions to specific genes, which in parallel enabled the
production of three, to our knowledge, novel derivatives. In
addition, work presented here provides evidence for a unique
‘‘macrocyclodehydration’’ reaction giving rise to the unique
amidine linkeage found in the bottromycin scaffold.287, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1279
Table 1. Proteins Involved in Bottromycin Biosynthesis
Protein Residues (aa) Annotation Proposed Function in Bottromycin Biosynthesis
BotRMT1 641 Radical SAM C-Methylation (of phenylalanine)
BotA 44 Structural gene Precursor peptide
BotC 434 Cyclodehydratase (YcaO-like family) Macrocyclodehydration (?)
BotCD 400 Cyclodehydratase (YcaO-like family
and docking_ocin superfamily)
Cyclodehydration during thiazole
ring formation (?)
BotRMT2 660 Radical SAM C-Methylation (of valines)
BotH 293 Putative a/b hydrolase Macrocycle or thiazole ring formation (?)
BotAH 465 Putative amidohydrolase Macrocycle or thiazole ring formation (?)
BotCYP 345 Cytochrome P450 enzyme Macrocycle or thiazole ring formation (?)
BotRMT3 681 Radical SAM C-Methylation (of proline)
BotR 184 Transcriptional regulator Pathway regulation
BotOMT 279 O-methyl transferase O-Methylation
BotT 441 Multidrug transporter Efflux pump, self-resistance
BotP 504 Leucyl-aminopeptidase Proteolytic cleavage
See also Figure S1 and Table S1.
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Identification of the Bottromycin Biosynthetic
Gene Cluster
Our initial attempts to identify the bottromycin biosynthetic
pathway were based on the assumption that the compound is
made via a nonribosomal peptide synthetase (NRPS) assembly
line, similar to most other cyclic peptide pathways analyzed to
date. Those systems usually exhibit a modular architecture, in
which each module incorporates one amino acid building block
to the growing peptide chain (Finking and Marahiel, 2004;
Schwarzer et al., 2003). Retrobiosynthetic analysis revealed
that the bottromycin peptide core almost certainly originates
from eight amino acids (Gly-Pro-Val-Val-Val-Phe-Asp-Cys),
which led us to predict an octamodular NRPS biosynthetic
machinery. In accordance with textbook biosynthetic logic, bot-
tromycin thiazole ring formation from a cysteine residue requires
the catalytic activity of a heterocyclization (HC) and an oxidation
(Ox) domain (Walsh et al., 2001; Schwarzer et al., 2003; Roy
et al., 1999; Walsh and Nolan, 2008), which should therefore
be included within the putative bottromycin assembly line. As
the identification of heterocycle-forming peptide pathways using
homologous and heterologous probes for HC and/or Ox
domains is well established (Cheng et al., 2002), we considered
this strategy to screen for the bottromycin biosynthetic pathway.
A cosmid library of the bottromycin producer Streptomyces sp.
BC16019 was constructed and analyzed for HC/Ox harboring
NRPS pathways by hybridization experiments (S.R., L.H., and
R.M., unpublished data). However, these efforts did not lead to
the identification of a genetic locus possibly involved in bottro-
mycin biosynthesis. To obtain comprehensive information about
all putative secondary metabolite pathways of S. sp. BC16019
whole-genome shotgun sequence data were generated using
the 454 technology. Detailed in silico analysis of the resulting
319 sequence scaffolds revealed no putative NRPS-dependent
bottromycin biosynthetic gene cluster, indicating that the com-
pound might rather derive from a ribosomal pathway. In this
case, one would expect a small precursor peptide-encoding1280 Chemistry & Biology 19, 1278–1287, October 26, 2012 ª2012 Egene accompanied by a number of ‘‘modifying genes’’ for craft-
ing the complex and bioactive bottromycin scaffold from a rather
simple, linear peptide chain assembled from the canonical
20 proteinogenic amino acids. Indeed, we were able to identify
a small open reading frame (orf; botA) in the sequence data
encoding the bottromycin octapeptide sequence, plus some
C-terminal extension. In silico analysis of the flanking regions
led to the identification of a number of genes encoding enzymes
that are most likely involved in the various posttranslational
modification (PTM) steps predicted for the maturation of the bot-
tromycin propeptide (see Figure 1 and Table 1). In order to
confirm that the identified chromosomal region encodes the
bottromycin biosynthetic pathway, we established a genetic
modification procedure for the producer strain to perform tar-
geted gene inactivation experiments. Using the suicide vector
pKC1132-botOMT-KO, one of the putative-modifying genes,
botOMT, was inactivated via homologous recombination, result-
ing in the mutant strain S. sp. BC16019::pKC1132-botOMT-KO.
High-performance liquid chromatography (HPLC)-mass spec-
trometry (MS) analysis in comparison to wild-type extracts
showed the abolishment of bottromycin production, confirming
the involvement of botOMT in bottromycin biosynthesis. At this
point, polar effects on genes located downstream could not be
excluded using the applied insertion strategy. Further experi-
ments (see subsection ‘‘Establishment and Optimization of
Heterologous Bottromycin Production’’) clearly established the
bot locus as the bottromycin biosynthetic gene cluster.
In Silico Analysis of the Bottromycin Biosynthetic
Pathway
The gene locus responsible for bottromycin biosynthesis was
identified through in silico analysis of genome data coupled
with targeted insertion mutagenesis as described above as
well as via heterologous expression of the entire pathway (see
subsection ‘‘Establishment and Optimization of Heterologous
Bottromycin Production’’). The pathway consists of (at least)
13 genes (bot genes) and spans about 18 kb (see Figure 2).
The botA gene encodes a 44-amino acid peptide and is flankedlsevier Ltd All rights reserved
Figure 2. Heterologous Bottromycin Production
(A) Inserts of the three expression constructs (pOJ436 derivatives) used for heterologous bottromycin production. The original cosmid DG2 was modified via
Red/ET recombineering to delete the 50-flanking region (orf7–orf20) by insertion of kanR and, in the next step, to insert the PermE* promoter upstream of botT
together with specR.
(B) Quantification of heterologous bottromycin production by HPLC-MS analysis of the culture extracts from different S. coelicolor mutant strains. Sections
of extracted ion chromatograms at m/z = 823.45 corresponding to the [M+H]+ ion of bottromycin A2 (1) are illustrated as representative readout of productivity.
The S. coelicolor A3(2) host strains contain one of the three expression constructs shown in (A). With S. coelicolor::DG2 and DG2-kan, ‘‘rifampicin-induced
mutagenesis’’ was performed (‘‘DG2-rif’’ and ‘‘DG2-kan-rif’’).
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8-residue highly modified macrocycle (see Figure 1). The BotA
precursor peptide is bipartite: it contains an N-terminal core
peptide as well as a C-terminal extension (the N-terminal methi-
onine is most likely cleaved off by a methionine aminopeptidase
during translation or by the putative peptidase BotP). This struc-
ture is unique among precursor peptides from ribosomal path-
ways described to date; in other precursors, the core peptides
are typically flanked by N-terminal leader sequences, and in
some cases additional C-terminal extensions are found (Oman
and van der Donk, 2010). It is frequently postulated that the
N-terminal leader sequences serve as a recognition motif for
the PTM enzymes and that they are removed in the last step of
the maturation process (Oman and van der Donk, 2010). The
absence of an N-terminal leader sequence in BotA indicates
that the C-terminal extension—or parts of it—functions as PTM
enzyme recognition sequence. Furthermore, as discussed for
the N-terminal leaders, some other functions can be attributed
to the C-terminal BotA sequence, for example, serve as secre-Chemistry & Biology 19, 1278–1tion signal, act as chaperone (in cis) and assist with folding, stabi-
lize the precursor against degradation, and/or keep the peptide
inactive during biosynthesis inside the cell (Oman and van der
Donk, 2010). (Final) Proteolytic cleavage of the C-terminal exten-
sion is most likely catalyzed either by the putative a/b-hydrolase
BotH or by BotP, which shows homology to leucyl aminopepti-
dases (Matsui et al., 2006). For some members of this group, it
could be shown that they also prefer methionine as N-terminal
amino acid, which correlates well with the predicted cleavage
site in BotA (see Figure 1) (Herrera-Camacho et al., 2007). The
highly modified bottromycin scaffold results from various PTM
reactions, and a number of candidate genes involved in these
processes have been identified in the bot locus—although
most of the encoded proteins exhibit only very low sequence
identity to proteins found in the common databases. This finding
and the associated difficulties in predicting enzyme function
from low similarity scores on the protein level are currently
a general challenge for the analysis of ribosomal peptide biosyn-
thesis pathways, which complicates the in silico analysis and287, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1281
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Ribosomal Bottromycin Biosynthesisfunctional gene annotation. However, a striking feature of the
bottromycin scaffold is its extensivemethylation pattern, and ac-
cording to our expectations a number of putativeS-adenosylme-
thionine (SAM)-dependent methyl transferases (MTs) could be
identified (BotRMT1, BotRMT2, BotRMT3, and BotOMT). Bo-
tOMT shows homologies to O-MTs and was therefore assumed
to be involved in O-methylation of the aspartate residue. The re-
maining three MTs (BotRMT1–BotRMT3) belong to the class of
radical SAM-dependent MTs (‘‘radical SAMs’’; Frey et al.,
2008; Atta et al., 2010) andwere expected to catalyze the various
C-methylations at the bottromycin scaffold. According to their
didomain protein architecture (N-terminal cobalamin binding
domain and C-terminal radical SAM domain), BotRMT1–
BotRMT3 belong to class B of the recently classified radical
SAM MTs (Zhang et al., 2012), which are indeed hypothesized
to contain members methylating unactivated sp3 carbons. This
finding is also in accordance with the proposedmethylation sites
of BotRMT1–BotRMT3 at proline, phenylalanine, and the two
valine residues. However, based on the in silico analysis, it is
clearly impossible to assign the exact function of each protein.
We therefore carried out further experiments to elucidate the
pathway (see subsection ‘‘Functional Studies on the Bottromy-
cin Methylation Pattern: A Suite of Hyperactive Methylases’’).
The thiazole ring is yet another structural feature of bottromycin,
occurring widespread in ribosomally made and nonribosomally
assembled peptide scaffolds (Walsh et al., 2001; Schwarzer
et al., 2003; Roy et al., 1999; McIntosh et al., 2009; Walsh and
Nolan, 2008; Nolan and Walsh, 2009). This heterocycle is typi-
cally installed by cyclodehydration starting from a cysteine
residue, the thiol of which attacks the carbonyl carbon of the
adjacent amino acid to form a thiazoline, which can subse-
quently undergo oxidation to form the thiazole. For the ribosomal
peptide microcin B17, it was shown that a three-protein
complex, consisting of a cyclodehydratase, a ‘‘docking protein,’’
and a flavin mononucleotide (FMN)-dependent dehydrogenase,
is required for thiazole ring formation (Li et al., 1996). Whereas
the function of the cyclodehydratase (cyclodehydration reaction)
and the dehydrogenase (thiazoline oxidation) was clearly as-
signed, the precise function of the ‘‘docking protein’’ remained
elusive until recently, and a direct role in regulating cyclodehy-
dratase activity and assembly of an active complex was debated
(Melby et al., 2011). However, a recent study demonstrates that
the ‘‘docking protein,’’ which belongs to the YcaO-like protein
family, itself catalyzes the cyclodehydration under consumption
of ATP (Dunbar et al., 2012). This study not only provided first
experimental evidence for the requirement of ATP-hydrolysis
for cyclodehydration reactions but also showed the dispens-
ability of the subunit formerly annotated as ‘‘cyclodehydratase’’
for the reaction. However, it could be shown that this protein can
increase the reaction rate by approximately three orders of
magnitude. When analyzing the bottromycin biosynthetic
pathway for enzyme candidates possibly involved in thiazole
ring formation, two putative ‘‘YcaO-like family proteins’’ (BotC
and BotCD) were identified, whereas genes encoding homologs
of the ‘‘cyclodehydratase’’ subunit could not be detected (see
below). Based on the above findings, we assume that BotC
and BotCD autonomously act as cyclodehydratases. Whereas
one of these enzymes is most likely involved in thiazoline ring
formation, the other candidate might play a role in the unique1282 Chemistry & Biology 19, 1278–1287, October 26, 2012 ª2012 E‘‘macrocyclodehydration’’ reaction as discussed below (see Fig-
ure 1).We speculate that BotCD is the enzyme involved in bottro-
mycin thiazole formation, because it shows not only homology to
YcaO-like family proteins but also to the ‘‘docking_ocin super-
family’’ of proteins (TIGR03604; members of this protein family
include enzymes related to SagD; Lee et al., 2008), which
includes ‘‘docking proteins’’ involved in heterocyclization reac-
tions in other ribosomal pathways. BotC, on the other hand,
would thus be a likely candidate for the unique catalyst perform-
ing the macrocyclodehydration discussed below. After cycliza-
tion conversion of thiazoline moieties into thiazoles usually
occurs via dehydrogenation. However, a putative dehydroge-
nase activity could not be detected in the bot locus, suggesting
that thiazole ring formation in bottromycin biosynthesis
proceeds via a different mechanism. The absence of a dehydro-
genasemight be explained by the requirements to form an ‘‘exo-
thiazole’’ moiety, which probably results from an oxidative elim-
ination reaction (see Figure 1). One possible scenario is an oxida-
tive decarboxylation after proteolysis of the C-terminal extension
sequence. However, we cannot exclude other ‘‘elimination
hypotheses,’’ which might rely on further premodifications of
the thiazoline ring (e.g., hydroxylation or dehydrogenation). Alter-
natively, precursor peptide proteolysis and subsequent oxida-
tive decarboxylation of the C-terminal cysteine might occur
before cyclodehydration. Similar reactions have been described
for the biosynthesis of aminovinyl-cysteine-containing ribosomal
peptides, including the generation of reactive ‘‘thio-enol’’ inter-
mediates via oxidative decarboxylation of C-terminal cysteine
residues (Sit et al., 2011). The enzymes involved were character-
ized as homo-oligomeric flavin-containing cysteine decarboxy-
lases, but no putative homolog of this enzyme family was found
encoded within the bottromycin biosynthetic gene locus. Appar-
ently, the underlying biochemistry for bottromycin ‘‘exo-thia-
zole’’ ring formation cannot be predicted based on the available
in silico data and requires further experimental studies.
Another intriguing modification unique for ribosomal peptide
biosynthesis is the formation of the bottromycin macrocycle
established between the N-terminal glycine and the second
valine residue. Similar to textbook cyclodehydration chemistry,
we propose a nucleophilic attack of the glycine amino group to
the valine carbonyl carbon, followed by dehydration. This trans-
formation may be seen as ‘‘macrocyclodehydration’’ reaction,
resulting in the formation of an amidine group, which is—to the
best of our knowledge—unique among all ribosomal peptides
biosynthetically characterized so far and also very rare among
other natural products. Coformycin (Nakamura et al., 1974)
and ectonine (Inbar and Lapidot, 1988), also described as pyro-
statin B (Castellanos et al., 2006), are examples of natural prod-
ucts containing this structural feature. Studies on the genetics
and biochemistry of ectoine metabolism revealed that the cyclic
amidine moiety is formed via a ‘‘cyclodehydratase’’-like reaction
similar to the macrocyclization mechanism we postulate for the
bottromycin biosynthesis. The enzyme involved is described as
ectoine synthase (EctC) and belongs to the family of carbon-
oxygen lyases. It is encoded in the ectoine biosynthetic gene
locus, which is found widespread in microorganisms (Pastor
et al., 2010), and could also be identified in the bottromycin
producer as well as in Streptomyces coelicolor. However, no
homolog of the ectoine synthase family could be identified inlsevier Ltd All rights reserved
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one of the putative cyclodehydratases (BotC and BotCD) might
be involved in ‘‘macrocyclodehydration.’’ BotC is the favored
candidate enzyme because of the arguments provided above.
However, we cannot exclude the involvement of ectoine biosyn-
thetic pathway enzymes in this reaction, as they are encoded in
the chromosomes of both the native and the heterologous
bottromycin producers. Additionally, there are some bot genes
with yet unassigned biosynthetic function, like botH, botAH,
and botCYP, encoding a putative a/b hydrolase, an amidohydro-
lase, and a P450 enzyme, respectively, which might be involved
in this unusual ‘‘macrocyclodehydration’’ reaction or in the
‘‘exo-thiazole’’ ring formation discussed above. Besides the
discussed enzyme candidates involved in the maturation of
the bottromycin precursor peptide, the biosynthetic gene cluster
encodes a putative transcriptional regulator (BotR) as well as
a putative multidrug transporter (BotT). The latter might play an
important role for the self-resistance of the bottromycin
producer, which is underpinned by results from genetic engi-
neering studies based on a heterologous expression system
(see next subsection).
Establishment and Optimization of Heterologous
Bottromycin Production
As genetic manipulation of the native bottromycin producer
S. sp. BC16019 turned out to be rather difficult and was
restricted to the established single-cross-over method with
very lowefficiency, we aimed to establish a heterologous expres-
sion system to further characterize and engineer bottromycin
biosynthesis. To mobilize the bottromycin pathway for expres-
sion in suitable host strains, the entire 18 kb biosynthetic
gene cluster was required to be subcloned on one physical
entity. We were able to identify a cosmid harboring the complete
target region plus some flanking sequence when screening the
gene library of the bottromycin producer with suitable probes
(cosmid DG2, see Figure 2A). As the pOJ436 cosmid backbone
already contains genetic elements for conjugation (origin of
transfer, oriT) and site-specific integration into Streptomyces
chromosomes (phage FC31 integrase gene and attachment
site; Bierman et al., 1992), the related host strains Streptomyces
coelicolor A3(2) and Streptomyces albus J1074 were directly
transformed with this construct. Transconjugants were verified
by PCR and subsequently analyzed for heterologous bottromy-
cin production. Parallel cultivations of host strains with and
without the expression construct in comparison to the native bot-
tromycin producer were carried out followed by HPLC-MS anal-
ysis of the culture extracts. Successful heterologous bottromycin
production could be detected for both of the expression hosts,
S. coelicolor::DG2 and S. albus::DG2, demonstrating that the
putative bottromycin pathway was complete and active in the
foreign circuits under control of its native regulatory elements.
Because the heterologous production yields in both hosts
were much lower compared to the native producer (1 mg/l
in S. albus and 4 mg/l in S. coelicolor; 100 times lower than
in native host), optimization approaches focused on the
S. coelicolor expression system were initiated. In a preliminary
step, the bulky expression construct was simplified by deletion
of a 16 kb insert fragment at the 50 end of the bot gene cluster.
This modification was performed via Red/ET recombineeringChemistry & Biology 19, 1278–1(Zhang et al., 1998, 2000), resulting in the integration of a kana-
mycin resistance gene to generate cosmid DG2-kan (see Fig-
ure 2A). As expected, subsequent heterologous expression in
S. coelicolor showed that this deletion does not significantly
affect the bottromycin production titer (see Figure 2B), and it
also confirmed our assumption that the excised genetic region
(orf7–orf20) is not required for bottromycin biosynthesis. Aiming
at improvement of bottromycin production titers, we next applied
an undirected approach based on the observation that certain
drug-resistance mutations in the rpoB gene (encoding the RNA
polymerase b-subunit), or the rpsL gene (encoding the ribosomal
S12 protein), may effectively enhance secondary metabolite
production in Gram-positive bacteria (Hu et al., 2002; Inaoka
et al., 2004; Shima et al., 1996; Hu and Ochi, 2001; Tamehiro
et al., 2003). Such mutations can be induced, for example, by
challenging the bacteria with rifampicin (mutations in rpoB) or
streptomycin (mutations in rpsL). After plating of the expression
strains S. coelicolor::DG2 and S. coelicolor::DG2-Kan on rifam-
picin-containing medium, spontaneous isolates resistant to the
antibiotic were obtained. Quantitative bottromycin production
analysis of clones from each ‘‘rifampicin mutagenesis’’ experi-
ment revealed mutant strains (S. coelicolor::DG2-rif and
S. coelicolor::DG2-Kan-rif) with a considerably higher production
titer (about ten times higher compared to the starting clones, see
Figure 2B). In parallel to this successful undirected approach, we
also considered targeted engineering strategies to improve bot-
tromycin production yields; because of the antibacterial activity
of bottromycin, we speculated that the self-resistance of the
host strain might be a limiting factor for the production titer.
Indeed we could show that the growth of S. coelicolor is already
heavily impaired at bottromycin concentrations of 2 mg/ml. In
light of this result, the putative efflux pump (BotT) encoded in
the bottromycin biosynthetic gene cluster represented a prom-
ising target for directed engineering approaches as we specu-
lated it to play a crucial role for self-resistance. To overexpress
the botT gene, its native promoter was replaced against the
strong PermE* promoter (Bibb et al., 1994) by insertion of a
spectinomycin resistance cassette via Red/ET recombineering
(see Figure 2A). S. coelicolor A3(2) wild-type was subsequently
transformed with the resulting construct DG2-kan-efflux-
ermE, and bottromycin production was quantified in com-
parison to S. coelicolor::DG2(-kan) and the corresponding ‘‘rif
mutants.’’ The HPLC-MS analysis revealed that, once more,
bottromycin production could be increased: the generated
S. coelicolor::DG2-kan-efflux-ermE expression host shows a
20 times higher production titer compared to S. coelicolor::
DG2(-kan) and an around two times higher production titer
compared to S. coelicolor::DG2(-kan)-rif. The generated data
on the successful enhancement of heterologous bottromycin
production for future experiments suggest combining both
strategies: the targeted approach (PermE* promoter insertion)
with the undirected approach (‘‘rifampicin mutagenesis’’). This
could potentially lead to a further increase of bottromycin
production yields.
Functional Studies on the Bottromycin Methylation
Pattern: A Suite of Hyperactive Methylases
A remarkable characteristic of the bottromycin scaffold is its
versatile methylation pattern, which can be attributed to a set287, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1283
Figure 3. Engineering and Characterization
of theBottromycin ‘‘MethylationMachinery’’
(A) Modification of the bottromycin biosynthetic
gene cluster. The four methyl transferase encod-
ing genes botRMT1, botRMT2, botRMT3, and
botOMT were deleted from the expression
construct DG2-kan-efflux-ermE in four orthogonal
Red/ET recombineering steps by insertion of
appropriate selection marker cassettes.
(B) Assigned fragment ions used for the com-
parison of the different bottromycin scaffolds
detected in (C)–(F). R1, R2, R3, and R4 = H or Me.
(C)–(F) High-resolution MS/MS fragmentation
analysis of bottromycin A2 reference substance
(C) and of bottromycin scaffolds detected in
extracts from the S. coelicolor A3(2) host strain
expressing modified versions of the bottromycin
biosynthetic gene cluster: botRMT3 deletion (D),
botRMT1 deletion (E), and botRMT2 deletion (F).
For the fragment spectrum from the botOMT
deletion experiment and a detailed comparison of
calculated and detected high-resolution masses
see Table S2 and Figure S1.
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Ribosomal Bottromycin Biosynthesisof four putative MTs encoded in the bot gene cluster. Based on
the in silico analysis, it was quite obvious that BotOMT might
catalyze O-methylation of the aspartate residue, whereas the
action sites of the three radical SAMs (BotRMT1–BotRMT3)
could not be assigned (C-methylation at C-7, C-19, C-26, and/
or C-33, see Figure 1). The established heterologous expression
system provided an excellent opportunity to accomplish func-
tional studies on the four MTs by performing targeted gene dele-
tion experiments, followed by the heterologous expression of the
modified pathways to elucidate the resulting bottromycin meth-
ylation pattern. In order to achieve this goal, four orthogonal gene
deletions were performed on the expression construct DG2-kan-
efflux-ermE using the Red/ET recombineering technology1284 Chemistry & Biology 19, 1278–1287, October 26, 2012 ª2012 Elsevier Ltd All rights res(Zhang et al., 1998, 2000). The respective
MT-encoding genes were replaced by an
antibiotic resistance gene (ampR, cmR, or
zeoR), and in case of botRMT1–botRMT3
the PermE* promoter was simultaneously
introduced in front of the downstream
genes to ensure proper transcription
(see Figure 3A). After S. coelicolor A3(2)
was transformed with the modified
constructs, the heterologous production
was studied by intensive HPLC-hrMS/
MS analysis on the culture extracts to
elucidate the methylation pattern of the
produced bottromycin derivatives. By
comparing the fragmentation pattern of
the detected bottromycin scaffolds, the
function of all four MTs could be unam-
biguously assigned (see Figure 3, Fig-
ure S1 [available online], and Table S2).
Three bottromycin derivatives can be
usually detected in extracts of the native
bottromycin producer, which differ in
the methylation pattern of the prolineresidue: the monomethylated main product bottromycin A2 (1)
plus unmethylated (bottromycin B2 (2)) and bimethylated (bottro-
mycin C2) minor components (Nakamura et al., 1967). Deletion
of botRMT3 resulted in the (exclusive) production of a bottromy-
cin scaffold exhibiting a molecular mass as well as a fragmenta-
tion pattern identical to authentic bottromycin B2 (2) reference
substance. Consequently, we can draw the conclusion that
botRMT3 catalyzes radical C-methylation of the proline residue.
After deleting botRMT1, again a bottromycin derivative with
amolecular mass identical to bottromycin B2 could be detected,
but numerous differences in the fragmentation pattern are
obvious. The mass of all ‘‘phenylalanine-containing’’ fragments
(3a and 3e) is reduced by 14 Dalton (Da) in comparison to theerved
Chemistry & Biology
Ribosomal Bottromycin Biosynthesiscorresponding fragments of bottromycin A2 and B2 (1a and 1e/
2e, 2a is also reduced by 14 Da as it contains the nonmethylated
proline residue). On the other hand, ‘‘non-phenylalanine-
containing’’ fragments (3b–3d) show the same mass as corre-
sponding fragments from bottromycin A2 (1b–1d), strongly
indicating that the three other relevant positions (proline and
two valine residues) are still methylated. Based on this, BotRMT1
was assigned to catalyze radical C-methylation of the phenylal-
anine residue. The deletion of the third radical SAM-encoding
gene (botRMT2) resulted in the production of a bottromycin scaf-
foldwith amolecular mass 28Da less than that of bottromycin A2
(1) and 14 Da less than that of bottromycin B2 (2), indicating the
presence of two unmethylated positions. The mass of fragment
4e verifies the presence of the methyl group at the phenylalanine
residue, whereas fragments 4b–4d indicate the ‘‘loss’’ of methyl
groups at two valine sites. This suggests that BotRMT2 is
involved in radical C-methylation of two of the three valine resi-
dues and therefore acts twice during bottromycin biosynthesis.
A similar analysis was carried out for the botOMT deletion exper-
iment (not shown in Figure 3) and provided experimental
evidence for the assigned function: O-methylation of the aspar-
tate residue. The produced ‘‘free acid’’ bottromycin scaffold
cannot be detected in strains expressing the complete pathway,
and the same holds true for compounds 3 and 4 identified after
botRMT1 and botRMT2 deletion. Thus, in addition to the findings
on the functional role of the bottromycin MTs, these experiments
also led to the production of three, to our knowledge, novel
bottromycin derivatives. It will be very interesting to analyze
the bioactivity of the modified scaffolds, which is currently
impeded by the very low production yields that also prevented
us from characterizing all structures via NMR experiments. The
reason(s) for the heavily reduced production yields in the deletion
experiments currently remain elusive. Reduced conversion rates
of desmethyl precursors by subsequent biosynthetic enzymes or
breakdown of the immunity system in the deletion mutants are
two of numerous possible explanations. As no cross-comple-
mentation reactions could be observed in the mutants analyzed,
we conclude that the three radical SAMs act very specifically
when crafting the bottromycin scaffold.
SIGNIFICANCE
Bottromycins represent an intriguing family of natural
products exhibiting promising activity against methicillin-
resistant Staphylococcus aureus and vancomycin-resistant
Enterococci. As protein synthesis inhibitors, they are re-
garded as attractive lead compounds for the development
of novel antibiotics because bottromycins target the unique
aminoacyl-tRNA binding site of the 50S ribosomal subunit.
Here, we discovered the bottromycin biosynthetic pathway
from Streptomyces sp. BC16019, providing evidence that
the heavily modified peptide scaffold is of ribosomal origin.
Quite unusually, the bottromycin precursor peptide lacks an
N-terminal leader sequence,which is regarded as a common
structural feature of ribosomally made natural product
peptide precursors. Our data also highlight the bottromycin
biosynthetic pathway as an outstanding example for a
variety of posttranslational modification reactions, which
in general are typical for ribosomal peptide biosyntheses.Chemistry & Biology 19, 1278–1Maturation of the bottromycin precursor peptide includes
macrocyclization via a unique amidine-forming ‘‘macrocy-
clodehydration,’’ a second cyclodehydration most likely
coupled to oxidative elimination building a thiazole ring,
proteolytic cleavage, and various unusual methylation reac-
tions. By use of synthetic biotechnology approaches, we
functionally elucidated the methylation steps involving the
action of an O-methyl transferase and three radical S-ad-
enosylmethionine (SAM)-dependent methyl transferases
required for alkylation of nonactivated carbons. The latter
enzyme class is currently not well characterized and thus
of special interest. These experiments also enabled the
production of three bottromycin derivatives based on a
heterologous expression system. Initial low yields were
addressed by application of targeted and undirected
approaches for production optimization. These resulted in
significant increases of bottromycin production titers in
the heterologous host now providing an important basis
for advanced structure and yield improvements. In a broader
sense, the discovery and characterization of the ribosomal
bottromycin pathway revealed exciting insights into
the biosynthesis of ribosomally made peptides—a bio-
technologically hardly exploited class of natural products
of increasing importance for drug discovery.
EXPERIMENTAL PROCEDURES
Strains and Culture Conditions
Streptomyces sp. BC16019, originally obtained from a soil sample collected in
Germany (Lerchen et al., 2006), is maintained in the culture collection of
InterMed Discovery GmbH, Dortmund, Germany, under liquid nitrogen. For
the present study, it was revived and cultivated at 30C and 180 rpm in liquid
yeast and malt extract with glucose (YMG) medium (Stadler et al., 2007).
Streptomyces coelicolor A3(2) (Bentley et al., 2002) and Streptomyces albus
J1074 (Chater and Wilde, 1976) were grown at 30C and 180 rpm in liquid
Tryptone soya broth (TSB) medium (Kieser et al., 2000), and their mutants
were cultivated in liquid TSB medium containing 60 mg/ml apramycin at
30C and 180 rpm. S. sp. BC16019, S. coelicolor A3(2), and Streptomyces al-
bus J1074 were grown on solid MS agar plates (Kieser et al., 2000). In addition
toEscherichia coliHS996 (Invitrogen, Carlsbad, CA, USA) used as general host
for molecular biology experiments, E. coli GB05-red (Fu et al., 2012) was
employed in Red/ET recombineering experiments (Zhang et al., 2000), and
E. coli ET12567/pUZ8002 (Kieser et al., 2000) was used for conjugation
experiments. All E. coli strains were grown in Luria Broth (LB) medium at
37C. If necessary, the medium was supplemented with the following antibi-
otics for screening appropriate mutants: chloramphenicol 30 mg/ml, spectino-
mycin 100 mg/ml, ampicillin 100 mg/ml, zeocin 25 mg/ml, kanamycin sulfate
50 mg/ml, and apramycin 60 mg/ml.
Sequencing and In Silico Analysis of the Streptomyces sp. BC16019
Genome
Total genomic DNA of S. sp. BC16019 was isolated in accordance with the
Kirby mix procedure as described previously (Kieser et al., 2000) and
sequenced by applying the 454 technology (Rothberg and Leamon, 2008),
including 2 kb paired-end reads. The resulting sequence data (2,228 contigs
and 319 scaffolds) were subsequently screened for putative open reading
frames (orfs) encoding peptides that contain the amino acid sequence of the
bottromycin scaffold (GPVVVFDC). For this, the EMBOSS ‘‘getorf’’ tool was
applied to identify sequences of ORFs (defined as region between two stop
codons), in accordance with the standard amino acid code. The output
sequence list of all possible, translated orfs was subsequently screened for
the GPVVVFDC-sequence using standard text editor software. A small orf
(later named botA) was identified, encoding this sequence plus some
C-terminal extension (see Figure 1).287, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1285
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Based on the data from the library screening (see Supplemental Experimental
Procedures), cosmid DG2 was chosen for further analysis, including whole
cosmid shotgun sequencing as described previously (Silakowski et al.,
1999). The obtained sequence of the 41 kb chromosomal fragment (insert
of cosmid DG2) was subsequently analyzed using bioinformatic tools. Predic-
tion of open reading frames was performed with FramePlot 4.0 (http://
nocardia.nih.go.jp/fp4/), and functional annotation was based on BlastP
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and Pfam (http://pfam.sanger.ac.uk/
search) searches. The Geneious 5.6.2 software packages (Biomatters, New
Zealand) was used for the analysis and annotation of DNA and protein
sequences. In addition to the putative 18 kb bottromycin biosynthetic gene
cluster (bot genes; see Figure 2 and Table 1) a number of flanking orfs
(orf1– orf20; see Figure 2 and Table S1) were identified.ACCESSION NUMBERS
The GenBank accession number for the bottromycin biosynthetic gene cluster
sequence fromStreptomyces sp. BC16019 reported in this paper is JX235926.SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, one figure, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2012.08.013.
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